Journal: Current Drug Delivery
Guest editor(s):Dr. Rahul Shukla
Co-Guest Editor(s): Professor Shubhini A. Saraf

Introduction

Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is comprehending and treating the mechanisms underlying neurodegenerative disorders, with a growing concern for neurodegenerative disorders, particularly in the cases of Parkinson’s, Alzheimer’s, ALS, and others, the need for advanced therapeutic and diagnostic approaches has become more pressing. Research on the regulation of these agents, utilizing nanotechnology platforms, has progressed into clinical phases. This special edition will concentrate on strategies for treatment and diagnosis employing advanced aspects of nanotechnology to combat neurodegenerative disorders. This study will also focus on elucidating the potential of emerging nanotechnologies in the targeted delivery of therapeutic agents, including small molecules, peptides, proteins, and nucleic acids, to ameliorate the pathological processes underlying neurodegenerative conditions It will serve as a valuable resource for researchers focused on nanotechnology-based techniques as tools for therapy and diagnosis, with a specific emphasis on precise delivery to the brain. The goal of this edition is to compile research and review articles to offer updated knowledge in the field of pharmaceutics.

Keywords

Nanotechnology, blood brain barrier, neurodegeneration, diagnosis, drug targeting

Sub-topics

- Implementation of nanotechnology-based methods for effectively delivering therapeutics to the central nervous system.
- Exploring potential of SiRNA and MiRNA for mitigating neurovegetative disease
- Targeting and diagnostic tools for addressing neurodegenerative diseases.
- Using both viral and non-viral vectors for gene delivery treatment
- Utilizing nanotechnology in Preclinical and clinical phases
- Utilizing the intranasal route for administering treatments for neurodegenerative disorders.
- Employing Alternative strategies for improve delivery in CNS like receptor mediated targeting, co-administration strategy, stimuli-based strategy, and many other advanced events.